Search Results

A live webcast and subsequent archived replay of the Company’s presentation may be accessed at https: (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media Dobson Media Group 203-258-0159 dennisdobsonjr@dobsonmediagroup.com

Sabbagh earned his medical degree from the University of Arizona College of Medicine in Tucson and his prolific author who has written and edited books on Alzheimer’s disease and has contributed to hundreds of medical “There is such a significant unmet medical need around the globe caused by Alzheimer’s disease and given I look forward to his guidance and contributions assisting our dedicated team in the process of bringing projected in any of such statements due to various factors, including the risks set forth in the Company’s most

precision medicine therapies to patients with devastating rare diseases, as well as the largest unmet medical Conference Call / Webcast Information Anavex will host a conference call and webcast today at 4:30 p.m The live webcast of the conference call can be accessed online at http://www.wsw.com/webcast/cc/avxl11 projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

ANAVEX®2-73-PDD-001 study results will be submitted for publication in a peer-reviewed medical journal debilitating disorder with significant co-morbidities and there has not been a mechanistically novel medication projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: Biology Volume 964 (2017) Sigma Receptors: Their Role in Disease and as Therapeutic Targets. [7] Source: https

Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the most frequent FXS published in the scientific journals Nature Scientific Reports [2] and the American Journal of Medical Autism spectrum disorder is a behavioral diagnosis while Fragile X syndrome is a medical/genetic diagnosis (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com [1]  https://fragilex.org/

Fragile X Syndrome (FXS) is the most common form of inherited intellectual disability and the most frequent Kaufmann, M.D., Chief Medical Officer of Anavex and corresponding author of the paper. Autism spectrum disorder is a behavioral diagnosis while Fragile X Syndrome is a medical/genetic diagnosis (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com [1] https://fragilex.org

Kaufmann, MD as Chief Medical Officer (CMO). Conference Call / Webcast Information The live webcast of the conference call can be accessed online at http (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most

Webcast Information: A live webcast of the presentation will be available via phone on 800-954-0621 and https (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media

discussion titled, “Fragile X Syndrome Case Study: From Preclinical to Clinical, Making Drug Development Efficient This Conference will provide an overview of global pricing, market access systems and cost management techniques, as well as in-depth discussion of some of the most current trends and changes. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most

A live webcast of the presentation will be available on http://www.veracast.com/webcasts/bio/ceoinvestor2018 (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media

“There is a growing unmet medical need for implementable and service-ready options for early Alzheimer “Blarcamesine’s precision-based approach holds great promise to substantially alleviate both the medical (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most

Study participants were allowed to stay on a stable regimen of anti-Parkinson's disease medications ( Rating Scale (MDS-UPDRS) is a commonly used tool to measure Parkinson disease (PD) progression. [4]https [5] https://www.anavex.com/post/anavex-announces-first-entire-clinical-alzheimer-s-gene-pathway-data-of-anavex -73-blarcamesine-in-people-with-parkinsons-disease/ [8]https://www.anavex.com/parkinsons-disease-data-mjf-conference /; https://www.anavex.com/anavex-awarded-grant-from-the-michael-j-fox-foundation-for-parkinsons-research